Cell-free DNA in Acute Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-30

Study Completion Date

2026-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and important procedural factors such as secondary embolisation and reperfusion outcomes, to analyse the correlation between blood and thrombus content of cfDNA and to investigate the specific source of cfDNA in distinct stroke subtypes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Blod Biomarkers for Stroke

NCT03941249

Stroke

UNKNOWN

Kinetics of Plasma and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Patients With Ischemic Stroke

NCT02860260

Ischemic Stroke

COMPLETED NA

PROgnostic Value of MicroParticles and Markers of Hemostasis in TIA and Ischemic Stroke

NCT05524506

Brain Ischemia Cerebral Ischemia Extracellular Vesicles +2 more

COMPLETED

Endothelial Function and Progenitor Cells in Acute Ischemic Stroke

NCT01289795

Ischemic Stroke

UNKNOWN

Multivariate Analysis of Serum High Sensitivity C-Reactive Protein in Patients With Acute Phase Stroke

NCT02171858

Stroke National Institutes of Health Stroke Scale Serum High Sensitivity C-Reactive Protein

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan)
* 18 years of age

Exclusion Criteria

* Patients currently undergoing immunological therapies.
* Patients with immunological diseases
* Patients with systemic infections at the time of admission

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No